Clinics in Dermatology
Volume 24, Issue 5 , Pages 363-373 , September 2006

Dermatomyositis

  • Jeffrey P. Callen, MD

      Affiliations

    • Division of Dermatology, University of Louisville School of Medicine, Louisville, KY 40202, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 502 583 1749; fax: +1 502 583 3028.
    • ,
  • Robert L. Wortmann, MD

      Affiliations

    • Department of Medicine, University of Oklahoma College of Medicine, Tulsa, OK 74135-2553, USA
    • Tel.: +1 918 660 3456; fax: +1 918 660 3444.

References 

  1. Callen JP. Dermatomyositis. Lancet. 2000;355:53–57
  2. Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995;122:715–724
  3. Targoff IN. Dermatomyositis and polymyositis. Curr Probl Dermatol. 1991;3:131–180
  4. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7 and 403-7 [two part article].
  5. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G. Tumor necrosis factor–a expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol. 2000;99:585–588
  6. Wanchu A, Khullar M, Sud A, Bambery P. Nitric oxide production is increased in patient with inflammatory myositis. Nitric Oxide. 1999;3:454–458
  7. Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T. Elevation of serum soluble tumor necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol. 2000;19:352–359
  8. Sugugiura T, Kawaguchi Y, Harigai M, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-5, and monocyte chemoattractant protein–1 production. J Immunol. 2000;164:6593–6600
  9. Nyberg P, Wikman A-L, Nennesmo I, Lundberg I. Increased expression of interleukin 1a and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol. 2000;27:940–948
  10. Werth VP, Callen JP, Ang G, Sullivan KE. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol. 2002;119:617–620
  11. Sarkar K, Weinberg CR, Oddis CV, et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum. 2005;52:2433–2438
  12. Pachman LM, Lipton R, Ransey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53:166–172
  13. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine. 1977;56:255–286
  14. Euwer RL, Sontheimer RD. Amyopathic DM (DM siné myositis). J Am Acad Dermatol. 1991;24:959–966
  15. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992;19:1385–1389
  16. Calabrese LH, Chou SM. Inclusion body myositis. Rheum Dis Clin North Am. 1994;20:955–972
  17. Dourmishev AL, Dourshimev LA. Dermatomyositis and drugs. Adv Exp Med Biol. 1999;445:187–191
  18. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J Am Acad Dermatol. 2002;46:626–636
  19. Troyanov Y, Targoff IN, Tremblay J-L, Goulet J-R, Raymond Y, Senecal J-L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies. Analysis of 100 French Canadian patients. Medicine. 2005;84:231–249
  20. Kasteler JS, Callen JP. Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. JAMA. 1994;272:1939–1941
  21. Ghali FE, Stein LD, Fine J-D, Burkes EJ, McCauliffe DP. Gingival telangiectases. An underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol. 1999;135:1370–1374
  22. Shannon PL, Ford MJ. Angiokeratomas in juvenile dermatomyositis. Pediatr Dermatol. 1999;16:448–451
  23. Rockerbie NR, Woo TY, Callen JP, Giustina T. Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol. 1989;20:629–632
  24. Stonecipher MR, Jorizzo JL, White WL, Walker FO, Prichard E. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: DM siné myositis?. J Am Acad Dermatol. 1993;28:951–956
  25. Cosnes A, Amaudric F, Gherardi R, et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol. 1995;131:1381–1385
  26. Cheong W-K, Hughes GRV, Norris PG, Hawk JLM. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol. 1994;131:205–208
  27. Woo TR, Rasmussen J, Callen JP. Recurrent photosensitive dermatitis preceding juvenile dermatomyositis. Pediatr Dermatol. 1985;2:207–212
  28. Callen JP. Photodermatitis in a 6-year-old child. Arthritis Rheum. 1993;36:1483–1485
  29. Zuber M, John S, Pfreundschuh M, Gause A. A young woman with a photosensitive pruritic rash on her face and upper trunk. Arthritis Rheum. 1996;39:1419–1422
  30. Callen JP. Photosensitivity in collagen vascular diseases. Semin Cutan Med Surg. 1999;18:293–296
  31. McCollough ML, Cockerell CJ. Vesiculo-bullous dermatomyositis. Am J Dermatopathol. 1998;20:170–174
  32. Requena L, Grilli R, Soriano L, Escalonilla P, Farina C, Martin L. Dermatomyositis with a pityriasis rubra pilaris–like eruption: a little-known distinctive cutaneous manifestation of dermatomyositis. Br J Dermatol. 1997;136:768–771
  33. Kaufmann R, Greiner D, Schmidt P, Wolter M. Dermatomyositis presenting as plaque-like mucinosis. Br J Dermatol. 1998;138:889–892
  34. Abernethy ML, Arterberry JF, Callen JP. Low-dose methotrexate as an adjunctive therapy with surgery for ectropion complicating dermatomyositis. Dermatology. 1996;192:153–155
  35. Launay D, Hatron PY, Delaporte E, Hachulla E, Devulder B, Piette F. Scleromyxedema (lichen myxedematosus) associated with dermatomyositis. Br J Dermatol. 2001;144:359–362
  36. Nousari HC, Ha VT, Laman SD, Provost TT, Tausk FA. ‘Centripetal flagellate erythema’: a cutaneous manifestation associated with dermatomyositis. J Rheumatol. 1999;26:692–695
  37. Huemer C, Kitson H, Malleson PN, et al. Lipodystrophy in patients with juvenile dermatomyositis—evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001;28:610–615
  38. Wortmann RL. Idiopathic inflammatory diseases of muscle. In:  Weisman ML,  Weinblatt ME,  Louie JS editor. Treatment of the rheumatic diseases. Philadelphia, PA: W.B. Saunders Co.; 2001;p. 390–402
  39. Spiera R, Kagen L. Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1998;10:556–561
  40. Marie I, Hatron P-Y, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol. 1998;25:1336–1343
  41. Selva-O'Callaghan A, Labrador-Horillo M, Munoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus. 2005;14:534–542
  42. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Insterstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297–301
  43. Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology. 2005;44:1282–1286
  44. Douglas WW, Tazezlaer HD, Hartman TE, et al. Polymyositis-dermatomyositis–associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182–1185
  45. Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, et al. Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol. 1996;14:373–379
  46. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100
  47. Siguregeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med. 1992;325:363–367
  48. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;5:9–13
  49. Airio A, Pukkala E, Isomäki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22:1300–1303
  50. El-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol. 2002;46:560–565
  51. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine. 1994;73:153–160
  52. Peng J-C, Sheem T-S, Hsu M-M. Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg. 1995;121:1298–1301
  53. Pautas E, Cherin P, Piette J-C, et al. Features of polymyositis and dermatomyositis in the elderly: a case-control study. Clin Exp Rheumatol. 2000;18:241–244
  54. Pachman LM. An update on juvenile dermatomyositis. Curr Opin Rheumatol. 1995;7:437–441
  55. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148:247–253
  56. Huemer C, Kitson H, Malleson PN, et al. Lipodystrophy in patients with juvenile dermatomyositis—evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001;28:610–615
  57. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P. Medium- and long-tern functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43:541–549
  58. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFa-308A allele in juvenile dermatomyositis. Arthritis Rheum. 2000;43:2368–2377
  59. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy. A unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 1997;36:178–182
  60. Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003;48:439–441
  61. Marie I, Joly P, Levesque H, et al. Pseudo-dermatomyositis as a complication of hydroxyurea therapy. Clin Exp Rheumatol. 2000;18:536–537
  62. Flendrie M, Vissers WHPM, Creemers MCW, de Jong EMCJ, van de Kerkhof PCM, van Riel PLCM. Dermatological conditions during TNF-a–blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666–R676
  63. Garcia J. MRI in inflammatory myopathies. Skeletal Radiol. 2000;29:425–438
  64. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70:360–374
  65. Targoff IN, Trieu EP, Sontheimer RD. Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis. Arthritis Rheum. 2000;43:S194A
  66. Komiya T, Negoro N, Kondo K, Miura K, Hirota Y, Yoshikawa J. Clinical significance of vonWillebrand factor in patients with adult dermatomyositis. Clin Rheumatol. 2005;24:352–357
  67. Callen JP. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol. 1982;6:253–259
  68. Callen JP. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer?. Arch Dermatol. 2002;138:969–971
  69. Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993;36:319–324
  70. Villalba L, Adams EM. Update on therapy for refractory dermatomyositis and polymyositis. Curr Opin Rheumatol. 1996;8:544–551
  71. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27:1542–1545
  72. Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95–102
  73. Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe?. Neurology. 2006;66:1245–1247
  74. Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52:3570–3578
  75. Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R. Intermittent high dose intravenous methylprednisolone (IV pulse) prevents calcinosis and shortens disease course in juvenile dermatomyositis (JDMS). Arthritis Rheum. 1994;37:R10A
  76. Sawhney S, Sidoti G, Woo P, Murray KJ. Clinical characteristics and outcome of idiopathic inflammatory myositis (IIM) in childhood: a 2 year follow up. Arthritis Rheum. 2000;43(Abstract Suppl):
  77. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27:2498–2503
  78. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392–399
  79. Saadeh CK. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arthritis Rheum. 2000;43:S193A
  80. Hengstman G, vandenHoogen F, vanEngelen B. Treatment of dermatomyositis and polymyositis with anti–tumor necrosis factor-α: long-term follow-up. Eur Neurol. 2004;52:61–63
  81. Levine TD. Rituximab in the treatment of dermatomyositis. An open-label pilot study. Arthritis Rheum. 2005;52:601–607
  82. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380–1384
  83. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000
  84. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis. Arthritis Rheum. 2002;46:467–474
  85. Mosca M, Stringini F, Carmignani CA, D'Ascanio A, Genazzani AR, Bombardieri S. Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy. Arthritis Rheum. 2005;53:119–121
  86. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439–2446
  87. Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719–1726
  88. Oryoji K, Himeji D, Nagafuji K, et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin Rheumatol. 2005;24:637–640
  89. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004;15:35–39
  90. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10:592–600
  91. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138:1231–1233
  92. Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32:754–757
  93. Kasteler JS, Callen JP. Low-dose methotrexate administered weekly in an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36:67–71
  94. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65–69
  95. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54:S139–S142
  96. Chung L, Genovese MC, Fiorentino D. Rituximab in the treatment of patients with dermatomyositis: 12 week interim analysis of a pilot project. (Abstract 555/F61—American College of Rheumatology, San Diego, CA, Nov. 15, 2005).
  97. Pachman LM, Abbott K, Sinacore JM, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148:247–253
  98. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19:138–141
  99. Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosis during diltiazem treatment of juvenile dermatomyositis. J Rheumatol. 1996;23:2152–2155
  100. Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvier R. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol. 2005;32:1837–1839
  101. Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine. 1999;78:139–147

PII: S0738-081X(06)00094-0

doi: 10.1016/j.clindermatol.2006.07.001

Clinics in Dermatology
Volume 24, Issue 5 , Pages 363-373 , September 2006

Article Tools

* Image Usage & Resolution